Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Samuel J. Poryanda"'
Autor:
John Koreth, Haesook T. Kim, Paulina B. Lange, Samuel J. Poryanda, Carol G. Reynolds, Sharmila Chamling Rai, Philippe Armand, Corey S. Cutler, Vincent T. Ho, Brett Glotzbecker, Rushdia Yusuf, Sarah Nikiforow, Yi-Bin Chen, Bimalangshu Dey, Malgorzata McMasters, Jerome Ritz, Bruce R. Blazar, Robert J. Soiffer, Joseph H. Antin, Edwin P. Alyea
Publikováno v:
Haematologica, Vol 103, Iss 3 (2018)
Aprior phase I/II trial of bortezomib/tacrolimus/methotrexate prophylaxis after human leukocyte antigen (HLA)-mismatched reduced intensity conditioning allogeneic hematopoietic stem cell transplantation documented low acute graft-versus-host disease
Externí odkaz:
https://doaj.org/article/14e5dcde8e624008856bae796592057f
Autor:
Sarah Nikiforow, Steven P. Margossian, Jerome Ritz, Sophie Silverstein, Soomin Kim, Haesook T. Kim, Philippe Armand, Samuel J. Poryanda, Jennifer Whangbo, Michelle A. Lee, Robert J. Soiffer, Christine Duncan, Corey Cutler, Sharmila Chamling Rai, Vincent T. Ho, Kelly Verrill, Nikola V. Mirkovic, John Koreth, Bruce R. Blazar, Edwin P. Alyea, Carol Reynolds, Jennifer T. Huang, Joseph H. Antin, Leslie Lehmann, Lauren Leonard
Publikováno v:
Blood advances. 3(17)
Low-dose interleukin-2 (IL-2) therapy for chronic graft-versus-host disease (cGVHD) generates a rapid rise in plasma IL-2 levels and CD4+CD25+CD127−Foxp3+ regulatory T-cell (CD4Treg) proliferation, but both decrease over time despite continued dail
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40c8584e4ebad421355680fb8dc40e04
https://pubmed.ncbi.nlm.nih.gov/31471324
https://pubmed.ncbi.nlm.nih.gov/31471324
Autor:
John Koreth, Evelyn Hipolito, William J. Savage, Vincent T. Ho, Marie Fields, Bruce R. Blazar, Edwin P. Alyea, Robert J. Soiffer, Roger Belizaire, Haesook T. Kim, Nikola V. Mirkovic, Jennifer Whangbo, Philippe Armand, Carol Reynolds, Corey Cutler, Jerome Ritz, Samuel J. Poryanda, Tomohiro Kubo, Joseph H. Antin, Sarah Nikiforow
Chronic graft-versus-host disease (cGVHD) affects >50% of hematopoietic stem cell transplant patients. Extracorporeal photopheresis (ECP), an immunomodulatory therapy, provides clinical benefit in steroid-refractory (SR) cGVHD, possibly via regulator
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f43d428edf7e3147d5ac703096f1f66
https://europepmc.org/articles/PMC6457231/
https://europepmc.org/articles/PMC6457231/
Autor:
Soomin Kim, Corey Cutler, Leslie Lehmann, Michelle A. Lee, Kelly Verrill, Jeremy M. Stewart, Sophie Silverstein, Sarah Nikiforow, Steven P. Margossian, Vincent T. Ho, C.N. Duncan, Lauren Leonard, Samuel J. Poryanda, John Koreth, Jennifer Whangbo, Robert J. Soiffer, Carol Reynolds, Philippe Armand, Jerome Ritz, Marie Fields, Bruce R. Blazar, Joseph H. Antin, Haesook T. Kim, Edwin P. Alyea
Publikováno v:
Biology of Blood and Marrow Transplantation. 25:S16-S17
Daily low-dose interleukin-2 (IL-2) at a fixed dose of 1 × 106 IU/m2/day leads to preferential expansion of CD4+CD25+CD127-Foxp3+ regulatory T cells (Treg) and clinical responses in 50-60% of adult patients with steroid-refractory chronic GVHD. Duri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c0fbc71c38d52f5882395865b9181a4c
https://doi.org/10.1016/j.bbmt.2018.12.084
https://doi.org/10.1016/j.bbmt.2018.12.084